Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons

EQS-News: BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives
EQS-News: BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives
EQS-News: BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives
EQS-Adhoc: BRAIN Biotech AG: Issuance of EUR 5 million convertible bond with exclusion of subscription rights
EQS-Adhoc: BRAIN Biotech AG: Issuance of EUR 5 million convertible bond with exclusion of subscription rights
EQS-Adhoc: BRAIN Biotech AG: Issuance of EUR 5 million convertible bond with exclusion of subscription rights
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adultshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults


Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the

Agilent Presents Solutions Innovation Research Awards to Drexel University and Prairie View A&M University Researchers:
Agilent Presents Solutions Innovation Research Awards to Drexel University and Prairie View A&M University Researchers


Agilent Technologies Inc. (NYSE: A) today announced the selection of Distinguished Professors Michel Barsoum and Yury Gogotsi at Drexel University and Professor Ananda Amarasekara at Prairie View

Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program

EQS-News: MEDICLIN presents preliminary figures for the 2023 financial year
EQS-News: MEDICLIN presents preliminary figures for the 2023 financial year
EQS-News: MEDICLIN presents preliminary figures for the 2023 financial year
Sensorion Announces its Participation in the Leerink Partners Global Biopharma Conference: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Announces its Participation in the Leerink Partners Global Biopharma Conference


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

Acadia Healthcare to Participate in Raymond James 45th Annual Institutional Investors Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Participate in Raymond James 45th Annual Institutional Investors Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Raymond James 45th Annual Institutional Investors Conference, which is being held March 3 - 6

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided

Xencor to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024


Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through

Vistagen to Present at TD Cowen 44th Annual Health Care Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at TD Cowen 44th Annual Health Care Conference


Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced

EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: 3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24
EQS-News: 3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24
EQS-News: 3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 26, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an

Chemed Reports Fourth-Quarter 2023 Results:
Chemed Reports Fourth-Quarter 2023 Results


Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Inogen Announces Fourth Quarter and Full-Year 2023 Financial Results: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen Announces Fourth Quarter and Full-Year 2023 Financial Results


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the

Dexcom Announces Upcoming Conference Presentation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James

Agilent Reports First-Quarter Fiscal Year 2024 Financial ResultsPhoto, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Agilent Reports First-Quarter Fiscal Year 2024 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.66 billion for the first quarter ended Jan. 31, 2024, a decline of 5.6% reported and 6.4% core(1) compared to the first quarter of

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for

Acadia Healthcare Reports Fourth Quarter 2023 Results: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports Fourth Quarter 2023 Results


Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2023.



Fourth Quarter Highlights

Aurinia to Participate in Upcoming Investor Healthcare Conferences: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia to Participate in Upcoming Investor Healthcare Conferences


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that management will be participating in the following upcoming investor conferences during the month of March

ICON plc to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON plc to Present at Upcoming Investor Conferences


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen